Judge sets aside Boston patent verdict
This article was originally published in Clinica
Executive Summary
A US federal judge last week ruled that a $324.4 million coronary stent patent decision in late 2000 against Boston Scientific and in favour of Johnson & Johnson should be overturned. The damages were set aside in March 2002. A new trial has been ordered by the judge, who also ruled that the stent of a co-defendant, Medtronic AVE, did not infringe J&J's patent (see Clinica No 939, p 10). J&J believes it will be able to reinstate the decision on appeal.